Westerkirk Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.8M Buy
13,207
+400
+3% +$409K 1.52% 14
2026
Q1
$11.8M Sell
12,807
-392
-3% -$397K 1.27% 16
2025
Q4
$14.2M Buy
13,199
+2,313
+21% +$2.21M 1.38% 13
2025
Q3
$8.31M Sell
10,886
-1,319
-11% -$982K 0.95% 18
2025
Q2
$9.51M Buy
+12,205
New +$9.48M 1.17% 15

Other funds holding LLY

Westerkirk Capital's LLY Position: Q2 2026 in Review

Westerkirk Capital increased its Eli Lilly (LLY) stake by 3.1% in Q2 2026, buying an estimated $409K and bringing the position to 13,207 shares worth $15.8M. The position accounts for 1.52% of the portfolio, ranked #14.

Westerkirk Capital first reported a position in LLY in Q2 2025 and has held it in 5 quarters since. 4,635 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Westerkirk Capital held 13,207 shares of Eli Lilly worth $15.8M as of Q2 2026.
  • Westerkirk Capital bought 400 Eli Lilly shares in Q2 2026, an estimated $409K.
  • Eli Lilly made up 1.52% of Westerkirk Capital's portfolio in Q2 2026, its #14 holding.
  • Westerkirk Capital first reported a position in Eli Lilly in Q2 2025 and has held it in 5 quarters since.
  • 4,635 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Westerkirk Capital's 13F filing for Q2 2026, filed 10 Aug 2026.